Halozyme Therapeutics (NASDAQ: HALO) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Halozyme Therapeutics to related companies based on the strength of its risk, earnings, valuation, profitability, dividends, analyst recommendations and institutional ownership.
This is a breakdown of recent ratings and price targets for Halozyme Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Halozyme Therapeutics Competitors||1377||4461||12271||311||2.63|
Halozyme Therapeutics presently has a consensus target price of $16.14, suggesting a potential upside of 0.96%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.79%. Given Halozyme Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Halozyme Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Halozyme Therapeutics||$134.17 million||-$95.85 million||-17.19|
|Halozyme Therapeutics Competitors||$470.18 million||$170.66 million||-6.30|
Halozyme Therapeutics’ competitors have higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Halozyme Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics’ competitors have a beta of 6.60, meaning that their average share price is 560% more volatile than the S&P 500.
Insider and Institutional Ownership
85.1% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Halozyme Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Halozyme Therapeutics Competitors||-4,762.52%||-354.75%||-43.31%|
Halozyme Therapeutics competitors beat Halozyme Therapeutics on 8 of the 12 factors compared.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.